Thanks for the excellent analysis and perspectives.

I sure hope that RVX isn't shooting too high foor the BETonMACE goals now that is 3 point MACE. From what I see the EMPA-REG trial achieved 13.2% RRR in MACE and LEADER was 12.7%. Absolute risk reduction was 1.6% points and 1.9% points respectively...very small even though statistically significant.

I do recall that apabetalone (rvx-208) achieved an RRR of 77% in patients with CVD, DM and low HDL in 6 months based on 5 point MACE.

I also recall that the data for 3 point MACE from SUSTAIN/ASSURE was very small and hence could provide little perspective re 3 point RRR but there did seem to be some numerical improvements??? (based on recall).

It would be better to set low targets and over achieve rather than having another June 2013 IMHO.

Toinv